Anti-DPP4 polyclonal antibody [Biotin]

DPP (dipeptidyl peptidase)-4 inhibitors are antidiabetic drugs that may increase heart failure in high-risk patients. NPY (neuropeptide Y) is coreleased with norepinephrine, causes vasoconstriction via the Y1 receptor, and is degraded by DPP4 to NPY (3-36) in vitro. NPY (3-36) decreases release of norepinephrine via the Y2 receptor. We tested the hypothesis that DPP4 inhibition would potentiate the vasoconstrictor effect of NPY. Eighteen nonsmokers (12 healthy controls and 6 with type 2 diabetes mellitus) participated in 1 of 2 randomized, double-blind, placebo-controlled crossover studies. First, subjects were randomized to order of treatment with sitagliptin 100 mg/d versus placebo for 7 days separated by 4-week washout. On the last day of treatment, NPY was infused by brachial artery and forearm blood flow was measured using plethysmography. Blood samples were collected after each dose. NPY infusions were repeated after 90-minute washout and intra-arterial enalaprilat. Second, 5 healthy subjects were randomized to crossover treatment with sitagliptin 100 mg/d plus valsartan 160 mg/d versus placebo plus valsartan. NPY infusions were performed on the seventh day of treatment. NPY caused dose-dependent vasoconstriction. During enalaprilat, sitagliptin significantly potentiated NPY-induced vasoconstriction in controls and diabetics (P0.02 for forearm blood flow in either group). Baseline norepinephrine release was increased during sitagliptin and enalaprilat, but not further by NPY. Sitagliptin increased the ratio of NPY to NPY (3-36). During valsartan, sitagliptin also significantly potentiated NPY-induced vasoconstriction (P=0.009 for forearm blood flow). Potentiation of endogenous NPY could contribute to cardiovascular effects of DPP4 inhibitors in patients taking an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker.

Aims: Exploring the CD26 expression in peripheral blood and T cells in Hashimoto's thyroiditis with normal thyroid function. And evaluating the association between CD26 expression and TGAb and TPOAb levels. Methods: We collected peripheral blood and thyroid tissues from healthy controls and HT patients. Then we measured circulating CD26 level via ELISA and membrane-bound CD26 on Th and Tc cells via flow cytometry. Immunochemistry is used to evaluate CD26 expression in thyroid tissue. Moreover, we analyzed the correlation between serum CD26 and autoantibodies and CD26 on T cells. Results: Compared with healthy controls, CD26 expression in serum and thyroid tissues were obviously lower in HT patients with normal thyroid function. And serum CD26 level was negatively related with TGAb. While no correlation was seen between membrane-bound CD26 and autoantibodies. There was no relation between serum CD26 and CD26 expression on T cells. Conclusions: Taken together, our results show that the level of serum CD26 was associated with TGAb in HT patients with normal thyroid function.